First Patient Treated in TRACE Renal Registry
NASHVILLE—Vanderbilt University Medical Center has treated the first patient to be included in a new registry—Tracking Renal Tumors After Cryoablation Evaluation (TRACE).

WILEX Successfully Completes Phase 1 Study
With the MEK Inhibitor WX-554
MUNICH—WILEX AG has successfully completed a phase 1 dose escalation study with the mitogen-activated protein kinase (MAPK) inhibitor, WX-554, demonstrating for the first time, activity in humans. Mitogen-activated protein kinase has been shown to play a central role in signal transduction and has been linked to a multitude of biological processes such as cell division, cell differentiation, and cell death.

Hopkins Team Manages RCC in Vena Cava
BALTIMORE—Renal cell carcinoma may metastasize to the inferior vena cava, posing a major risk of thrombosis from its location in this largest of veins.

“If it’s just blocking the vena cava and not invading into the wall,” says Mohamad Allaf, MD, “for many people, this occlusion is the biggest threat to their life.”